Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Jul 12;6(4):e00421.
doi: 10.1002/prp2.421. eCollection 2018 Jul.

Screening of anticancer drugs to detect drug-induced interstitial pneumonia using the accumulated data in the electronic medical record

Affiliations

Screening of anticancer drugs to detect drug-induced interstitial pneumonia using the accumulated data in the electronic medical record

Yoshie Shimai et al. Pharmacol Res Perspect. .

Abstract

Because drug-induced interstitial pneumonia (DIP) is a serious adverse drug reaction, its quantitative risk with individual medications should be taken into due consideration when selecting a medicine. We developed an algorithm to detect DIP using medical record data accumulated in a hospital. Chest computed tomography (CT) is mainly used for the diagnosis of IP, and chest X-ray reports, KL-6, and SP-D values are used to support the diagnosis. The presence of IP in the reports was assessed by a method using natural language-processing, in which IP was estimated according to the product of the likelihood ratio of characteristic keywords in each report. The sensitivity and the specificity of the method for chest CT reports were 0.92 and 0.97, while those for chest X-ray reports were 0.83 and 1, respectively. The occurrence of DIP was estimated by the patterns of presence of IP before, during, and after the administration of the target medicine. The occurrence rate of DIP in cases administered Gefitinib; Methotrexate (MTX); Tegafur, Gimeracil, and Oteracil potassium (TS-1); and Tegafur and Uracil (UTF) was 6.0%, 2.3%, 1.4%, and 0.7%, respectively. The estimated DIP cases were checked by having the medical records independently reviewed by medical doctors. By chart review, the positive predictive values of DIP against Gefitinib, MTX, TS-1, and UFT were 69.2%, 44.4%, 58.6%, and 77.8%, respectively. Although the cases extracted by this method included some that did not have DIP, this method can estimate the relative risk of DIP between medicines.

Keywords: adverse drug reaction; electronic medical record; imaging report; interstitial pneumonia; natural language processing.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Dataset for learning data and test data 1. The same numbers of CT reports for the IP and Non‐IP groups were selected by a radiologist from clinical data warehouse data. The CT reports in each group were allocated to the learning dataset and test data 1. Reports for X‐ray performed on the day nearest to the CT examination within 3 months were selected in the same patients in the learning data and test data 1
Figure 2
Figure 2
Dataset for test data 2. One hundred CT reports were selected at random for test data 2. Test data 2 was classified into IP and Non‐IP Group by a radiologist. X‐ray reports which was performed on the nearest day from CT examination within 3 months were selected for test data 2 of X‐ray

Similar articles

Cited by

References

    1. Arondekar B, Curkendall S, Monberg M, et al. Economic burden associated with adverse events in patients with metastatic melanoma. J Manag Care Spec Pharm. 2015;2:158‐164. - PMC - PubMed
    1. Stark RG, John J, Leidl R. Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: a modelling approach. BMC Health Serv Res. 2011;11:9. - PMC - PubMed
    1. Vouk K, Benter U, Amonkar MM, et al. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries. J Med Econ. 2016;19:1‐43. - PubMed
    1. Frank C, Himmelstein DU, Woolhandler S, et al. Era of faster FDA drug approval has also seen increased black‐box warnings and market withdrawals. Health Aff (Millwood). 2014;8:1453‐1459. - PubMed
    1. Jefferys DB, Leakey D, Lewis JA, Payne S, Rawlins MD. New active substances authorized in the United Kingdom between 1972 and 1994. Br J Clin Pharmacol. 1998;2:151‐156. - PMC - PubMed

Publication types

MeSH terms

Substances